Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
ASCO GU 2021: Recommendations From Dr. Eric Jonasch
- Written by
-
Eric
Jonasch
MD
Dr. Eric Jonasch, member of the Advisory Board of PracticeUpdate Oncology, recommends the following presentations at the upcoming ASCO Genitourinary Cancers Symposium, which will take place virtually on February 11 through February 13, 2021.
Poster Session: Renal Cell Cancer
Available starting on Thursday, February 11, 2021; 8:00 AM EST
309 Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920. SS Tykodi, LN Gordan, RS Alter, et al
313 Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. NM Tannir, RJ Motzer, L Albiges, et al
Oral Abstract Session: Renal Cell Cancer
Saturday, February 13, 2021; 1:00 PM–2:15 PM EST
269 Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). RJ Motzer, C Porta, M Eto, et al
270 Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. SK Pal, C Tangen, IM Thompson, Jr, et al
272 Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). TK Choueiri, TM Bauer, DF McDermott, et al
273 The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. TM Bauer, TK Choueiri, KP Papadopoulos, et al
Rapid Abstract Session: Renal Cell Cancer
Saturday, February 13, 2021; 3:45 PM–4:30 PM EST
276 Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). CL Gan, S Dudani, AL Schmidt, et al
Additional Info
Disclosure statements are available on the authors' profiles:
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.